---
title: "BrainAurora Medical Technology Limited (06681.HK)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/06681.HK.md"
symbol: "06681.HK"
name: "BrainAurora Medical Technology Limited"
industry: "Health Care Technology"
---

# BrainAurora Medical Technology Limited (06681.HK)

| Item | Detail |
|------|--------|
| Industry | Health Care Technology |
| Location | HK Market |
| Website | [66nao.cn](https://66nao.cn) |

## Company Profile

BrainAurora Medical Technology Limited provides system integral software solutions for hospitals and research projects in Mainland China. The company develops medical-grade digital therapy (DTx) products for cognitive impairment. It offers the evaluation and intervention of cognitive impairments to ...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-03-02T04:30:12.000Z

**Overall: C (0.42)**

**Industry**: Health Care Technology

| Metric | Value |
|--------|-------|
| Industry Ranking | 3 / 7 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 80.34% |  |
| Net Profit YoY | 11.80% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 23.52 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 6.38B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 184.85M |  |


**Multi Score**: C

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 257.00% | A |
| Profit Margin | -123.37% | E |
| Gross Margin | 40.83% | B |

#### Growth Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 80.34% | A |
| Net Profit YoY | 11.80% | C |
| Total Assets YoY | 130.76% | A |
| Net Assets YoY | 161.08% | A |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -81.06% | D |
| OCF YoY | 80.34% | A |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.33 | D |

#### Debt Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 65.87% | D |


```chart-data:radar
{
  "title": "Longbridge Financial Score - BrainAurora Medical Technology Limited",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "257.00%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-123.37%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "40.83%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "A",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "80.34%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "11.80%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "130.76%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "161.08%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-81.06%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "80.34%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.33",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "D",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "65.87%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | MEDLIVE (HK.2192) | B | B | E | A | B | B |
| 02 | XUNFEIHEALTH (HK.2506) | D | A | C | D | C | C |
| 03 | BRAINAURORA-B (HK.6681) | B | A | D | D | B | C |
| 04 | YIDU TECH (HK.2158) | D | D | D | A | D | C |
| 05 | SINOHEALTH HLDG (HK.2361) | A | D | C | A | C | C |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -25.50 | 5/7 | - | - | - |
| PB | 21.67 | 7/7 | 35.88 | 29.82 | 24.96 |
| PS (TTM) | 31.46 | 7/7 | 65.38 | 53.50 | 41.46 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-05-11T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.33 |
| Highest Target | 7.50 |
| Lowest Target | 7.50 |

## References

- [Company Overview](https://longbridge.com/en/quote/06681.HK/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/06681.HK/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/06681.HK/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.